871112-36-6

Basic information

• Product Name: 1-BOC-4-(3,4-DIFLUOROPHENYL)-4-HYDROXYPIPERIDINE
• Synonyms: 1-BOC-4-(3,4-DIFLUOROPHENYL)-4-HYDROXYPIPERIDINE;1-Boc-4-(3,4-difluorophenyl)-4-piperidinol
• CAS NO: 871112-36-6
• Molecular Formula: C₁₆H₂₁F₂NO₃
• Molecular Weight: 313.342
• Mol File: 871112-36-6.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-BOC-4-(3,4-DIFLUOROPHENYL)-4-HYDROXYPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-(3,4-DIFLUOROPHENYL)-4-HYDROXYPIPERIDINE(871112-36-6)
• EPA Substance Registry System: 1-BOC-4-(3,4-DIFLUOROPHENYL)-4-HYDROXYPIPERIDINE(871112-36-6)

Safety Data

• Hazardous Substances Data: 871112-36-6(Hazardous Substances Data)

Usage

Chemical class

Piperidines

Specific type

Piperidine derivative

Structural features

1-Boc-protecting group
Difluorophenyl substituent
Hydroxy group at the 4-position of the piperidine ring

Applications

Building block in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds

Versatility

Allows for the introduction of diverse chemical functionalities

Boc protecting group

Enables selective manipulation of the hydroxy group

Value

Valuable tool in chemical synthesis due to its unique structure and functional groups

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 90897-92-0 3,4-difluorophenylmagnesium bromide 
• 348-61-8 1-bromo-3,4-difluorobenzene 

Downstream Products

• 233261-74-0 4-(3,4-difluorophenyl)-4-hydroxypiperidine 
• 725739-63-9 4-(3,4-difluoro-phenyl)-3,6-dihydro-2H-pyridine-1-sulfonyl chloride 
• 751478-17-8 4-(3,4-difluorophenyl)-1,2,3,6-tetrahydropyridine 
• 574007-37-7 tert-butyl 4-(3,4-difluorophenyl)-3,6-dihydro-2H-pyridine-1-carboxylate 

Relevant articles and documents

MODULATORS OF TREX1

Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositons thereof, which are useful for treating a variety of conditions associated with TREX1.

DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION

The present invention relates to compounds of the formulae (4), (5) or (6), and their use in the treatment of central nervous system disorders.

Design and synthesis of orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugs

A novel series of TNF inhibitors was identified based on the screening of existing MMP inhibitor libraries. Further SAR optimization led to the discovery of a novel lead compound. Its synthesis, efficacy in experimental animal models, and pharmacokinetic